Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. (note: metadata listed "Kiora Pharmaceuticals Inc" but the filing text identifies "EyeGate Pharmaceuticals, Inc.") on January 4, 2018, covering events effective as of January 1, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Promotion: Sarah M. Romano, CPA, was promoted from Interim Chief Financial Officer to Chief Financial Officer, effective January 1, 2018.
- Compensation Adjustment: A new offer letter was executed establishing an annual base salary of $200,000 and a target bonus of up to 25% of the base salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that there are no related party transactions between the Company and Ms. Romano.
Key Facts for Investor Verification
- Verify the exact name of the registrant (EyeGate Pharmaceuticals, Inc.) against the metadata provided.
- Review Exhibit 10.1 for the complete terms of the employment agreement with the new CFO.
- Confirm the tenure of the new CFO, who has served in an interim capacity since February 1, 2017.